Who We Are
Anew Oncology, Inc. (“Anew”, “AOI”, or the Company) is a private, commercial-stage specialty oncology company founded with a vision to build a portfolio of more affordable, life-saving medicines for cancer patients around the world. Lower cost, more affordable and life-saving drugs are now an imminent reality in the global oncology market due to prior and upcoming patent expirations on several blockbuster anti-cancer drugs. Unlike other “generic drugs”, generic oncology drugs hold their value and their profit margins due to the requirement for special “high containment” manufacturing facilities, minimized competition in this therapeutic area, and the ongoing “drug shortages” of many of these life-saving generic drug products. This reality, coupled with ever increasing pressure and demand for more competitively priced oncology products signals a considerable emerging new commercial opportunity. Anew Oncology has positioned itself to be at the forefront of this opportunity by establishing a competitive pipeline of branded Onco-generics, Onco-Betters and Onco-Biologic products, whose success has been plotted and is driven by a highly motivated and experienced management team executing on the commercial launch programs and the drug development plans. Experts at product launch and marketing in international markets guarantees success outside the US and Europe.
Oncology Drug Market
Our Mission is to Develop, Market and Sell More Affordable Life-Saving Products for Cancer Patients
Anew Oncology, Inc.
Currently headquartered in New York, NY, with affiliate offices in Seattle, San Francisco, Boston and Washington D.C, Anew Oncology, Inc. has established an operational presence in Europe (London U.K. and Hamburg Germany) via Anew Oncology Ltd. and plans to have affiliate offices in Mumbai, India, Tel Aviv Israel, and Seoul, South Korea.